Clinical Trial Update: A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR) [Phase 1, Phase 2]

View source ↗

Summary

A single-arm Phase Ib/II trial of pacritinib in 1q21.3 amplified solid tumors with IRAK1 pathway activation is described, with breast cancer listed among the co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pacritinib (pacritinib)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING